

Financial Results **for the 1Q/FY 2009 Ending March 31, 2010**

August 3, 2009
Yoshihiko Hatanaka
CFO and Chief Strategy Officer
Astellas Pharma Inc.

Cautionary Statement Regarding Forward-Looking Information

This material includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties.

Actual financial results may differ materially depending on a number of factors including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launch, pricing and product initiatives of competitors, the inability of the company to market existing and new products effectively, interruptions in production, infringements of the company's intellectual property rights and the adverse outcome of material litigation.

This material contains information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations nor provide medical advice of any kind.

Summary of Financial Results for 1Q/FY2009





(¥ billion)

	1Q/08 Actual	1Q/09 Actual	Change	2Q/09 Forecasts	Progress	Factors
Net sales	254.5	252.1	-2.4	486.0	51.9%	Forex impact -16.8 Voluntary withdrawal by US theft accident -4.5
COG COG ratio	74.3 29.2%	75.5 30.0%	+1.2 +0.8ppt			Product mix +1.5ppt (incl. voluntary withdrawal by theft) Forex impact on elimination of unrealized gain -0.9ppt
SGA SGA ratio	71.5 28.1%	68.9 27.3%	-2.6 -0.8ppt			Forex impact
R&D R&D ratio	40.3 15.9%	38.4 15.3%	-1.9 -0.6ppt	81.0	47.5%	In-license fee -6.4 Increase of development costs and depreciation of new research facilities in Japan
OP OP ratio	68.2 26.8%	69.1 27.4%	+0.8 +0.6ppt	117.0	59.1%	Forex impact -3.0
Ordinary income	73.1	69.6	-3.5	119.0	58.5%	Decrease of financial income Currency exchange loss
Net income	45.1	44.0	-1.1	73.0	60.3%	Improvement of tax rate


Forex	1Q/08	1Q/09	Change	09 forecasts
USD	105 yen	97 yen	-7	100 yen
EUR	163 yen	133 yen	-31	130 yen

Sales by Geographical Area

-Sales Increase globally on a local currency basis-



Vesicare



1Q/09 Growth Rate

- Japan: 18%
- North America: 32% (USD)
- Europe: 23% (EUR)
- Asia: 169% (Local currency)


Market Share

- Japan : 44% (1Q/09, NHI Drug price basis)
- US : 17% (TRx, Week of Jul.17)
- Europe : 32% (May 09, cash basis)

Launched: More than 50 countries/areas

- China (expected in 09)

Fungard/Mycamine



1Q/09 Growth Rate

- Japan : -0.1%
- North America : 17% (USD)
93% (excl. Voluntary withdrawal by theft)
- Asia : 184% (Local currency)
- Europe: €1 million (actual sales)

Market Share


- Japan : 51%* (1Q09)
- US : 45%** (May 09)

➔ No.1 position as a candidin agent

Launched: More than 20 countries/areas

- Indonesia (expected in 09)
- India (expected in 09, licensed to GSK)
- Europe: Launched in 16 countries

Prograf




1Q/09 Growth Rate

- Japan: 20%
- North America : 1% (USD)
10% (excl. voluntary withdrawal by theft)
- Europe : 15% (EUR)
- Asia : 48% (local currency)

Topics

- Japan
Additional indication for ulcerative colitis (Jul. 09)
- US
TRx share: KTx 89%, LTx90%, HTx77%(CNI, Mar. 09)
Use of Prograf and MMF as an adjunct therapy
in KTx (approved in May 09)
No generic launched during 1Q/09
- EU
Sales of Advagraf: €20MM
No generic launched and price reduction during 1Q/09
- Advagraf launched in Asia
HongKong (Jan. 09)
Korea, Taiwan, Thailand (expected in 09)

Harnal



1Q/09 Growth Rate

- Japan : 2%
- Europe : 5% (EUR)
- Asia : 23% (Local currency)
- Bulk and Royalty : 56% (EUR)

US Flomax

- Sales : \$591M (2Q/CY09, +27%)
- TRx Share: 41% (Jun. 09)
- Submitted pediatric data to the FDA at the end of Jun. 09

TOCAS

- Sales in Europe : €32MM
- Launched in Indonesia in Apl. 09

Japan : Sales of Major Products

Japan

(¥ billion)

	081Q	091Q	Change
Total Rx	124.8	128.3	+3.4
Lipitor	24.4	25.6	+1.2
Micardis/Micombi	16.4	19.3	+2.9
Gaster	14.0	13.4	-0.6
Harnal	9.2	9.4	+0.1
Prograf	7.1	8.5	+1.4
Myslee	6.3	7.1	+0.8
Seroquel	5.4	6.0	+0.5
Vesicare	4.8	5.6	+0.8
Celecox	2.3	3.6	+1.2
Geninax	1.1	2.0	+0.9
Iribow	-	0	+0
Bonoteo	-	0.7	+0.7

Product Lineup

Japan

	Major Products	New Products	Late-stage Pipeline
CV Endocrine Kidney	<p>Lipitor</p> <p>Micardis</p>	<p>Micombi</p>	<p>YM150</p> <p>ASP1941</p> <p>ASP1585</p>
Urology	<p>Harnal</p>	<p>Vesicare</p>	<p>YM178</p> <p>ASP3550</p>
Transplant Immunology	<p>Prograf Transplant, RA, LN, MG</p>	<p>Prograf UC</p>	<p>FK506 (MG all)</p>
Orthopedic		<p>Celecox</p> <p>Bonoteo</p>	<p>YM177 (Acute pain)</p> <p>YM529 (1mo. formulation)</p>
Anti-infective		<p>Geninax</p>	
CNS	<p>Myslee</p> <p>Seroquel</p> <p>Luvox</p>		<p>ASP8825</p>
Gastro-intestinal	<p>Gaster</p>	<p>Irribow</p>	

Product Lineup

North America

	Major Products	Collaboration (New)	Late-stage Pipeline
Hospital	Trans-plant	Prograf	ASP0485
	AI	Mycamine	telavancin
		AmBisome	
CV	Adenoscan/Lexiscan		RSD1235
	Vaprisol		
Dermatology	Protopic		
	Amevive		
Urology PCP	VESIcare	Sumavel™ DosePro™*	YM178
	Flomax		
			YM150, ASP1941 YM155, etc.. ••

*"Sumavel" and "DosePro" are trademarks of Zogenix, Inc.

Product Lineup

Europe

Major Products

In-licensed (new)

Late-stage Pipeline

Specialists

Prograf/Advagraf

Mycamine

Protopic

Qutenza

Telavancin

YM178

**Solifenacin •
Tamsulosin**

**Urology
PCPs**

Vesicare

**Harnal/
Harnal OCAS**

Eligard

**YM150
ASP1941
YM155 etc
⋮**

Product Lineup

Asia

Major Products

Prograf

Harnal (incl. D and OCAS)

Gaster

Perdipine

Nasea

Dorner

New Products/In-licensed

Advagraf

Vesicare

Mycamine

Irribow

TMX-67 (febuxostat) *only in Taiwan



Global Pipeline

Status of Pipeline

Red: Changes from the previous announcement

Green : Japan Local

Yellow : New Indication, New Formulation

Pink : In-house Global

Orange : Licensed-in Global

	Filed	P3	P2	P1
Urology	YM617(LUTs, J)	YM178 (OAB, E, US, J)	ASP3550 (J)	ASP0265 ASP3652 ASP7035
	YM617(Pediatric, US)# #Submitted the pediatric data to the FDA	solifenacin/ tamsulosin (E)	YM905(D tablet, J)	
Transplant Immunology Inflammation	FK506 (Myasthenia gravis, J)	YM177 (Acute pain, J)	ASP0485 (E, US) ASP9831 (E)	ASK8007 ASP015K ASKP1240 ASP3291
Anti-Infective	telavancin (cSSSI,US) telavancin (HAP,US)	telavancin (E)	ASP2151 (US, J)	telavancin (J)
Diabetes Cardiology Renal	RSD1235 (US) YM086 (Diabetic nephropathy, J)	YM150 (VTE, J, A) ASP1585 (J)	YM150 (VTE, E, US) YM150 (AF, E, J, A) ASP1941 (US, J) YM311 (E) * ASP1517 (US)* YM533 (J)	YM311(J) * ASP1517(J) *
CNS	ASP8825 (Restless legs syndrome, J)			ASP2905 ASP0777 FK949E
Oncology			AGS-1C4D4 (E, US) YM155 (E, US)	AGS-16M18 AGS-8M4 YM155 (J)
Others		YM443 (J) YM529 (1M, J)	YM443 (US) YM060 (E)	

Progress in Pipeline Status from May 09

Project	Indication	Area	Stage	Remarks
Prograf	Use of Prograf and MMF as an adjunct therapy for the prophylaxis of organ rejection in kidney transplantation	USA	Approved	Approved in May
Modigraf (tacrolimus granules)	Prophylaxis of transplant rejection in kidney, liver or heart allograft recipients	Europe	Approved	Approved in May
Prograf	Ulcerative colitis	Japan	Approved	Approved in July
Celecox	Lumbago, Scapulohumeral periarthritis, Cervico-omo-brachial syndrome and Tendinitis/tendosynovitis	Japan local	Approved	Approved in June
tamsulosin	Pediatric neurogenic bladder	USA	Submitted the data to the FDA	Submitted the pediatric data to the FDA (June 2009)
ASP8825	Restless legs syndrome	Japan local	Preparation for filing	Plan to file by using data of foreign-clinical trials
YM155	Breast cancer, Non-Hodgkin's lymphoma, Melanoma	USA/Europe /Japan	P2	Target cancers were decided

Progress in Pipeline Status from May 09 (P1, etc.)

New P1 Projects

Project	Indication	Stage	Remarks
ASP3291	Ulcerative colitis	P1	Entered into P1
FK949E	Major depressive disorder	P1	Entered into P1
ASP1517(FG-4592)	Renal anemia	P1	P2 in USA, Entered into P1 in Japan*

Discontinued Project

FK199B modified release (Insomnia)

*Licensed territory: Europe, Japan etc.

mirabegron (YM178) Development Progress

NDA Filing Expected in FY2010

▶ Japan P3 started

Study outline

- Double-blind, placebo-controlled study
- Primary endpoint: Change of number of micturitions per 24 hours
- Treatment period: 12 weeks
- Enrollment: 990 patients


▶ EU/US P3 long-term safety study: Enrollment completed

▶ Data presentation: Plan to present Europe P2b results at international urological congress in 2010.

YM150 Development Progress

Clinical trial status

- VTE: Japan/Asia P3 studies started, AF: Europe/Japan/Asia P2b started.
- Total exposure >2,500: No major safety concerns reported.



Results of VTE P2a and AF P2a in Japan/Asia

- VTE: Consistent safety/efficacy compared to European P2.
AF: Safety confirmed up to 3 months.
- Data to be presented at upcoming international conferences.

YM155 Survivin suppressant: Oncology

▶ Three Target Indications:

□ Breast Cancer

Metastatic, HER2 negative; Combination with Docetaxel

□ Non-Hodgkin's Lymphoma

Relapsed, and are ineligible for BMT* or relapsed post transplant;
Combination with Rituximab

*BMT: Bone Marrow Transplantation

□ Melanoma

Unresectable Stage III or Stage IV; Combination with Docetaxel

▶ Phase 2 Start: 4Q/CY09 (expected)

▶ Target Product Profile:

- A “First-in-class” survivin suppressant
- Combination with other anticancer drugs for enhanced activity with minimal additional toxicity compared to anticancer drug alone

ASP8825: Prodrug of Gabapentin

NDA Filing Expected in Japan in 2nd half of FY2009

▶ **Target indication: Restless Legs Syndrome**

▶ **We will file without Japanese P3 data to use data of foreign-clinical trials (bridging strategy).**

■ **Discontinuation of development for painful diabetic neuropathy in Japan was decided.**

[Reason] Japanese P2 trial indicated difficult to demonstrate efficacy.

What is Restless Legs Syndrome (RLS) ?

Symptoms of RLS*

Uncomfortable Sensations of Legs



Cause difficulty in falling or staying asleep
Significant influence for QOL

Number of patients in Japan

According to several large-size investigations, consultation rate of RLS is estimated 2-5 %.

Number of potential patients (2008) : 3.9 million **

**Number of diagnosed patients:
470 thousand ****

** Rate of diagnosed patients is estimated as 12% according to epidemiological research by Kageyama et al.

[Diagnosis of RLS]***

- An urge to move the legs usually accompanied or caused by uncomfortable and unpleasant sensations in the legs.
- The urge to move or unpleasant sensation begin or worsen during periods of rest or inactivity, such as lying or sitting.
- The urge to move or unpleasant sensations are partially or totally relieved by movement.
- The urge to move or unpleasant sensations are worse in the evening or night than during the day.

***International RLS study group, 2003

To Enhance Our Enterprise Value (1)

R&D

Establishment of Joint Venture with Maxygen

- **Purpose : To discover, research and develop multiple protein pharmaceutical programs, including Maxygen's MAXY-4 program and other early stage programs (Target indication : autoimmune diseases and transplant rejection)**
- **Ownership of interest : Maxygen 83 : Astellas 17**
- **Option granted to Astellas: To acquire all of Maxygen's ownership interest in the joint venture at specified exercise prices over the three-year term of the option**

Construction of Fermentation Technology Research Building in Toyama Plant

- **Purpose : To ensure stable global supply of active pharmaceutical ingredient for clinical trial material as the development of candidate compounds obtained through fermentation-based drug discovery research**
- **Construction : To be initiated around September 2009 and completed in 2010**

To Enhance Our Enterprise Value (2)

Sales & Marketing

Commercialization Agreement for Qutenza with NeurogesX in Europe

- Indication: Peripheral neuropathic pain in non-diabetic adults
- Mechanism: Highly-concentrated capsaicin cutaneous patch
- Development stage: Approved in May 2009
- Initial Payments: €30MM for Qutenza, €5MM for a license option of NGX-1998
- Area: European Economic Area, Middle East and Africa

License Agreement for TMX-67 (febuxostat) with Teijin in Taiwan

- Indication: Hyperuricemia in patients with gout
- Mechanism: Highly potent, non-purine drug that selectively inhibits xanthine oxidase
- Astellas will manage the approval process and handle sales of TMX-67 after its commercial launch, which is targeted in 2013

To Enhance Our Enterprise Value (3)

Sales & Marketing

Co-Promotion Agreement in the US for Sumavel™ DosePro™ with Zogenix

- Indication: Acute treatment of migraine attacks and acute treatment of cluster headache episodes
- Generic name (mechanism): sumatriptan injection (5-HT_{1B/1D} receptor agonist) needle-free delivery system
- Development stage: Approved
- Right: Co-promotion (Zogenix focusing primarily on Neurologists, Astellas focusing mostly on primary care physicians)

Astellas Farma Brasil

- Establishment: July 2009
- Purpose: To enter the significantly growing market (Brazil is the world 10th pharmaceutical market with sales of \$12.5 bii. in 2008)
- Products: Omnic/Omnic Ocas

Achieved our goal of creating a direct presence in all the BRICs